Document:

QuickLinks
 -- Click here to rapidly navigate through this document

Exhibit 10.24  

 
 

AMENDED AND RESTATED SUPPLY AGREEMENT (2006)    
    

        This amended and restated agreement is between Biomira International Inc., a Barbados corporation with offices located at Belleville, St. Michael, Barbados
("BIOMIRA"), and Merck KGaA, a German corporation with offices located at Darmstadt, Germany ("MERCK") and is effective as of March 1, 2006. 

        WHEREAS
BIOMIRA and MERCK entered into an amended and restated supply agreement effective as of May 7, 2001 (the "2001 SUPPLY AGREEMENT") in relation to, inter alia, the
manufacture and supply by BIOMIRA to MERCK of BLP25; 

        AND
WHEREAS BIOMIRA, Biomira B.V. and MERCK entered into a letter of intent effective as of January 26, 2006 to amend, inter alia, certain provisions of the 2001 SUPPLY AGREEMENT; 

        AND
WHEREAS BIOMIRA and MERCK now wish to amend and restate the 2001 SUPPLY AGREEMENT in accordance with, inter alia, such letter of intent, all upon the terms and subject to the
conditions set forth in this AGREEMENT; 

        NOW,
THEREFORE, in consideration of the premises and covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which is hereby agreed to by the
parties, and intending to be legally bound hereby, the parties hereto agree as follows: 

ARTICLE 1

DEFINITIONS  

Section 1.1    Meaning  

        Whenever a term is written in this AGREEMENT with all capital letters it shall have the following meaning: 

	1.1.1
	"AFFILIATES"
means any business entity that directly or indirectly controls, is controlled by, or is under common control with either party to this AGREEMENT. A business entity
shall be deemed to "control" another business entity if it owns, directly or indirectly, more than fifty percent (50%) of the outstanding voting securities, capital stock, or other comparable equity
or ownership interest of such business entity. If the laws of the jurisdiction in which such entity operates prohibit ownership by a party of more than fifty percent (50%), control shall be deemed to
exist at the maximum level of ownership allowed by such jurisdiction;

	1.1.2
	"AGREEMENT"
means this amended and restated supply agreement, together with all schedules hereto and any amendments to or restatements of this amended and restated supply agreement;

	1.1.3
	"BIOMIRA
COST OF GOODS" includes, but is not limited to, with respect to PRODUCT in the TERRITORY, [+] 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES. 

 

	1.1.4
	"BIOMIRA
MANUFACTURING KNOW-HOW" means the proprietary information and data relating to the manufacture of PRODUCT owned by BIOMIRA or licensed in by BIOMIRA with the
right to sublicense in the manner contemplated by this AGREEMENT and which directly relate to the manufacture of PRODUCT;

	1.1.5
	"BIOMIRA
TECHNOLOGY" has the meaning attributed to that term in section 1.1.8 of the COLLABORATION AGREEMENT;

	1.1.6
	"BLA"
means a biological license application, or any equivalent, as such term is used in the regulations of the FDA or EMEA;

	1.1.7
	"BLP25"
has the meaning attributed to that term in section 1.1.9 of the COLLABORATION AGREEMENT;

	1.1.8
	"cGMP"
means, as applicable, current good manufacturing practices as defined in the FDA rules and regulations, 21 CFR Parts 210 and 211, Japanese Koseisho Regulations and the
provisions of the European Commission's GMP Directive 2003/94/EC and of the EU GMP Guide, all as may be amended from time to time;

	1.1.9
	"CLINICAL
DEVELOPMENT" means all activities required for MARKET APPROVAL of PRODUCT in the TERRITORY (including without limitation clinical trials and toxicology studies), as well
as all clinical activities desirable for optimized marketing of PRODUCT in the TERRITORY (including without limitation phase IIIb and phase IV studies). This term does not include any
activities necessary for manufacture and/or supply of PRODUCT;

	1.1.10
	"CMO
AGREEMENT" has the meaning attributed to that term in section 2.11.1 of this AGREEMENT;

	1.1.11
	"COLLABORATION
AGREEMENT" means that certain amended and restated collaboration agreement effective as of March 1, 2006 and made between Biomira B.V. and MERCK, together
with any amendments to or restatements of such amended and restated collaboration agreement;

	1.1.12
	"COMPONENTS"
mean the antigen, adjuvant and/or structural lipids necessary to manufacture the PRODUCT;

	1.1.13
	"COMPLIANCE
AUDIT" has the meaning attributed to that term in section 2.2.8.3 of this AGREEMENT;

	1.1.14
	"CONFIDENTIAL
INFORMATION" has the meaning attributed to that term in section 3.1 of this AGREEMENT;

	1.1.15
	"DOSE"
means with respect to PRODUCT and for purposes of section 2.12.2 of this AGREEMENT, the amount of PRODUCT currently (i.e., as at the date of this AGREEMENT) specified
to be taken at one time (being four vials each containing 250 micrograms of lipopeptide); 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES. 

2

 

	1.1.16
	"DRUG
SUBSTANCE" means BLP25 Small Liposomes (BLP25-SL), a transient entity in the manufacturing process of PRODUCT;

	1.1.17
	"EFFECTIVE
DATE" shall mean March 1, 2006, or such other date as BIOMIRA and MERCK may agree upon in writing;

	1.1.18
	"EMEA"
means the European Medicines Agency or any successor agency;

	1.1.19
	"END
USER" has the meaning attributed to that term in section 1.1.21 of the COLLABORATION AGREEMENT;

	1.1.20
	"EVENT"
and "EVENT AUDIT" have the meanings attributed to such terms in section 2.2.8.2 of this Agreement;

	1.1.21
	"EXECUTION
DATE" shall mean the first day on which the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of
1976, as amended, in relation to the notification and report of the parties with respect to the COLLABORATION AGREEMENT has expired or been terminated, or such other date as
BIOMIRA and MERCK may agree upon in writing;

	1.1.22
	"FDA"
means the United States Food and Drug Administration or any successor agency;

	1.1.23
	"FIELD"
shall mean the use of BLP25 for the prevention and/or treatment of cancers in humans;

	1.1.24
	"INDICATION"
has the meaning attributed to that term in section 1.1.27 of the COLLABORATION AGREEMENT;

	1.1.25
	"LAUNCH"
shall mean, with respect to PRODUCT in a particular country in the TERRITORY, the date of the first arm's length SALE of PRODUCT in such country after receipt of MARKET
APPROVAL for PRODUCT in such country;

	1.1.26
	"MANUFACTURING
LICENSE" has the meaning attributed to that term in section 2.12.1.1 of this AGREEMENT;

	1.1.27
	"MAJOR
MARKET" shall mean any one of Germany, France, United Kingdom, Italy, Spain or Japan, and "MAJOR MARKETS" shall mean all of such countries;

	1.1.28
	"MARKET
APPROVAL" shall mean, with respect to PRODUCT in a particular country in the TERRITORY, the date upon which the last of all governmental or regulatory
approvals required for the sale of PRODUCT in that country has been granted, including price approval for PRODUCT (if required);

	1.1.29
	"MERCK
SUB-SUPPLIERS" has the meaning attributed to that term in section 2.11.1 of this AGREEMENT; 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES. 

3

 

	1.1.30
	"NA
TERRITORY" shall mean, collectively, Canada (including Quebec) and its territories and the United States of America and its territories;

	1.1.31
	"NET
SALES" has the meaning attributed to that term in section 1.1.38 of the COLLABORATION AGREEMENT;

	1.1.32
	"ORIGINAL
EFFECTIVE DATE" shall mean May 7, 2001;

	1.1.33
	"PHASE III
TRIAL" means a study in humans of the efficacy and safety of PRODUCT which is designed to demonstrate statistically whether PRODUCT is effective
for use in a particular indication and which is prospectively planned to form one of the pivotal trials required in order to obtain MARKET APPROVAL for PRODUCT;

	1.1.34
	"PRODUCT"
shall mean BLP25;

	1.1.35
	"QUALITY
AGREEMENT(S)" has the meaning, as applicable (i.e., supply for clinical trial purposes versus supply for commercial purposes), attributed to that term in
section 2.2 of this AGREEMENT;

	1.1.36
	"REJECTION
DATE" has the meaning attributed to that term in section 2.2.5 of this AGREEMENT;

	1.1.37
	"REJECTION
NOTICE" has the meaning attributed to that term in section 2.2.5 of this AGREEMENT;

	1.1.38
	"ROW
NET SALES" means the aggregate NET SALES of PRODUCT in the ROW TERRITORY;

	1.1.39
	"ROW
TERRITORY" shall mean all countries in the world except the NA TERRITORY;

	1.1.40
	"SALE"
includes, with respect to PRODUCT, the sale to and/or use thereof by an END USER, and "SOLD" and "SELL" have a corresponding meaning;

	1.1.41
	"SPECIFICATIONS"
means the specifications (including specifications relating to minimum shelf life and stability) in relation to PRODUCT set forth in Schedule 1 to this
AGREEMENT or, where not so specified, as agreed upon in writing by BIOMIRA and MERCK and incorporated by reference as part of Schedule 1, as all such specifications may be amended from time to
time by the written agreement of BIOMIRA and MERCK;

	1.1.42
	"SPECIFIED
QUARTER" has the meaning attributed to that term in section 2.2.1 of this AGREEMENT;

	1.1.43
	"STEERING
COMMITTEE" has the meaning attributed to that term in section 1.1.45 of the COLLABORATION AGREEMENT; 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES. 

4

 

	1.1.44
	"TERRITORY"
shall mean, collectively, the NA TERRITORY and the ROW TERRITORY; and

	1.1.45
	"THIRD
PARTY LICENSES" has the meaning attributed to that term in section 1.1.49 of the COLLABORATION AGREEMENT. 

ARTICLE 2

SUPPLY AND DELIVERY OF PRODUCT  

Section 2.1    Supply of PRODUCT in the TERRITORY  

        BIOMIRA shall sell to MERCK, and MERCK shall purchase from BIOMIRA, with respect to the NA TERRITORY and the ROW TERRITORY, in finished, but unlabelled vials
(i.e., not "ready for sale" form, unless otherwise agreed in writing by BIOMIRA and MERCK) such quantities of PRODUCT as are ordered by MERCK from time to time in accordance with the terms of this
AGREEMENT for SALE in the NA TERRITORY and the ROW TERRITORY. Subject to section 2.12 of this AGREEMENT, MERCK shall order all PRODUCT required pursuant to the COLLABORATION AGREEMENT or
otherwise exclusively from BIOMIRA. MERCK shall be responsible for advising BIOMIRA of all applicable country specific requirements in connection with the SALE of PRODUCT in the NA TERRITORY and the
ROW TERRITORY. The SALE of all PRODUCT in the NA TERRITORY and the ROW TERRITORY by MERCK and its AFFILIATES and their respective
permitted sublicensees, assignees and transferees shall be governed by the terms of the COLLABORATION AGREEMENT. 

Section 2.2    Forecasting; Purchase Orders; QA and QC  

        Subject to section 2.12 of this AGREEMENT, MERCK (on behalf of itself and its AFFILIATES, distributors and other agents) agrees to exclusively purchase
PRODUCT from BIOMIRA pursuant to this AGREEMENT. Further, additional provisions in relation to quality assurance and regulatory requirements shall be set out in one or more separate quality agreements
(the "QUALITY AGREEMENT(S)"). For PRODUCT to be utilized for clinical trial purposes, BIOMIRA and MERCK entered into a QUALITY AGREEMENT on July 26, 2006, a copy of which is attached hereto as
Schedule 2. With respect to the commercial supply of PRODUCT, BIOMIRA and MERCK shall enter into a separate QUALITY AGREEMENT (or amend and restate the July 26, 2006 QUALITY AGREEMENT)
upon such terms and conditions as BIOMIRA and MERCK may agree upon in writing, which QUALITY AGREEMENT shall be attached hereto as Schedule 3. With respect to PRODUCT: 

	2.2.1
	BIOMIRA
agrees to supply to MERCK and MERCK agrees to purchase exclusively from BIOMIRA such quantities of PRODUCT as MERCK shall from time to time request (in accordance with this
section 2.2.1) by written purchase order from BIOMIRA, provided such purchase orders shall always be for commercially efficient lot sizes of PRODUCT (recognizing that such lot sizes are subject
to variances for, among other things, quality control and quality assurance purposes). By September 30, 2006, MERCK shall provide BIOMIRA with a twelve (12) month rolling forecast of
MERCK's requirements (per calendar quarter during such twelve (12) month period) for PRODUCT, specifying any country specific requirements, if any, for the period 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES. 

5

 

	

	January 1,
2007 to and including December 31, 2007. On January 1, 2007, and thereafter on the first day of each following calendar
quarter, MERCK shall provide to BIOMIRA an updated rolling forecast by adding to the remaining twelve (12) months covered by the previous forecast the next following calendar quarter (e.g., on
January 1, 2007 MERCK is required to update the previous forecast by providing BIOMIRA with MERCK's requirements for the calendar quarter January 1, 2008 to and including
March 31, 2008). With respect to each calendar quarter specified in any such rolling forecast (a "SPECIFIED QUARTER"), MERCK shall, at a minimum, purchase from BIOMIRA, by firm purchase order
[+] However, BIOMIRA and MERCK agree that it is in the interests of both parties to seek to meet all demand for PRODUCT and, in the foregoing regard, BIOMIRA and MERCK will
work together to resolve any capacity issues. Further, BIOMIRA and MERCK agree to consider revisions to the procedures set forth in this section 2.2.1 as required and agreed upon in writing in
the future.

	2.2.2
	With
each delivery of PRODUCT to MERCK, BIOMIRA shall provide a certificate of analysis (in substantially the form attached to this AGREEMENT as Schedule 4), a certificate of
compliance for each lot of PRODUCT comprising such delivery and a completed batch record form. BIOMIRA shall also provide to MERCK such documentation under the control of BIOMIRA required by
applicable law and regulation in order to allow MERCK to release and SELL PRODUCT in the NA TERRITORY and the ROW TERRITORY;

	2.2.3
	all
PRODUCT purchased hereunder by MERCK from BIOMIRA shall conform at the time of delivery by BIOMIRA to MERCK to the SPECIFICATIONS applicable to PRODUCT, shall have been
manufactured in accordance with cGMP and all applicable laws and regulations in the country of manufacture (and, if MERCK has in a timely manner informed BIOMIRA in writing thereof, the specific
applicable laws and regulations of the United States of America and the European Union and, if BIOMIRA agrees in writing (such agreement not to be unreasonably withheld), any other country in the ROW
TERRITORY), and no PRODUCT shall, at the time of delivery by BIOMIRA to MERCK, be adultered or misbranded within the meaning of the United States Food, Drug and Cosmetics
Act and/or the Public Health Service Act or, to the extent applicable, be an article which may not be introduced into interstate
commerce under section 505 of the United States Food, Drug and Cosmetics Act and section 351 of the Public Health
Service Act;

	2.2.4
	all
PRODUCT purchased hereunder by MERCK from BIOMIRA shall at the time of delivery by BIOMIRA to MERCK have such shelf life as is agreed to in writing by BIOMIRA and MERCK,
provided that [+]

	2.2.5
	upon
receipt of any PRODUCT, MERCK may inspect and test the PRODUCT for conformance to the applicable SPECIFICATIONS (and material deviations from the applicable batch records) and
may, up to the date which is sixty (60) days after the date of receipt by MERCK of such shipment of PRODUCT and the applicable certificate of analysis, certificate of compliance and 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES. 

6

 

	

	batch
record form (the "REJECTION DATE"), reject the same by sending to BIOMIRA written notice (the "REJECTION NOTICE") of such rejection on or before the
REJECTION DATE (specifying the nature of such non-conformance) if the PRODUCT does not conform to the applicable SPECIFICATIONS. MERCK shall be deemed (except with respect to latent
defects as at the time of delivery of PRODUCT by BIOMIRA to MERCK (and not as a result of subsequent legal, regulatory or other similar changes), in which case this provision shall apply after the
expiration of sixty (60) days after the discovery of such latent defect) to have accepted a particular delivery of PRODUCT if MERCK has not sent to BIOMIRA a REJECTION NOTICE in connection with
such delivery on or before the REJECTION DATE related to such delivery. If BIOMIRA disagrees with the alleged non-conformity of the PRODUCT with the applicable SPECIFICATIONS, quality
representatives of BIOMIRA and MERCK shall negotiate in good faith to assess whether there has been a non-conformity and the corrective action, if any, to be taken by BIOMIRA. In the event
the quality representatives of BIOMIRA and MERCK are unable to agree on whether or not there has been a non-conformity, then an independent laboratory or QA consultant, mutually agreed
upon in writing by the parties, shall analyze samples of the alleged non-conforming PRODUCT to determine compliance with the applicable SPECIFICATIONS. MERCK and BIOMIRA shall be bound by
the laboratory analysis of such alleged non-conforming PRODUCT. The cost incurred in connection with retaining the independent laboratory or QA consultant shall be borne by MERCK if the
PRODUCT in question is found to conform to the applicable SPECIFICATIONS and by BIOMIRA if the PRODUCT in question is found not to conform to the applicable SPECIFICATIONS. Notwithstanding the
foregoing procedure to determine whether or not the PRODUCT conforms with the SPECIFICATIONS, BIOMIRA shall replace the batch under investigation from existing inventory (to the extent available) if
so requested in writing by MERCK. To the extent it is determined that any PRODUCT supplied by BIOMIRA to MERCK under this AGREEMENT does not conform to the applicable SPECIFICATIONS or materially
deviates from the applicable batch records, BIOMIRA's sole obligation and MERCK's sole remedy shall be to have BIOMIRA replace such non-conforming PRODUCT from existing inventory (to the
extent available) at no additional cost to MERCK as promptly as practicable. BIOMIRA shall reimburse MERCK for all reasonable costs and expenses incurred by MERCK to, at BIOMIRA's option, destroy such
nonconforming PRODUCT or ship such nonconforming PRODUCT to such destination as BIOMIRA may specify in writing to MERCK. MERCK shall pay BIOMIRA for all conforming PRODUCT, including, without
limitation, the original PRODUCT supplied as well as any and all replacement PRODUCT supplied;

	2.2.6
	To
enable MERCK to inspect and test the PRODUCT for conformance to the applicable SPECIFICATIONS, BIOMIRA shall use commercially reasonable efforts to transfer to MERCK the test
assays necessary for the testing of PRODUCT as described in Section 2.2.5 above, provided that BIOMIRA and MERCK acknowledge that BIOMIRA's resources required in connection with such transfer
obligations are limited and may be required elsewhere; 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES. 

7

 

	2.2.7
	BIOMIRA
shall inspect, or cause to be inspected, in accordance with the applicable SPECIFICATIONS and as otherwise agreed in writing by the parties, each lot of PRODUCT prior to
delivery thereof to MERCK. With respect to the results of such inspection in relation to a particular lot of PRODUCT, BIOMIRA shall notify MERCK in a timely manner of any deviations from the
applicable SPECIFICATIONS. A certificate of analysis for each lot delivered shall set forth the items tested and the test results. A certificate of compliance and a batch record form for each lot
shall also be provided by BIOMIRA to MERCK wherein BIOMIRA shall certify that the PRODUCT in question has been produced in accordance with the applicable SPECIFICATIONS, cGMP and all applicable laws
and regulations in the country of manufacture (and, if MERCK has in a timely manner informed BIOMIRA in writing thereof, the specific applicable laws and regulations of the United States of America
and the European Union and, if BIOMIRA agrees in writing, any other country in the ROW TERRITORY). BIOMIRA shall also indicate on the certificate of compliance that all lot production and control
records and PRODUCT master files have been reviewed and approved by or on behalf of the appropriate quality control unit of BIOMIRA. BIOMIRA shall send, or cause to be sent, such certificates to MERCK
concurrently with or prior to the shipment of each lot of PRODUCT;

	2.2.8
	

	2.2.8.1
	subject
to section 2.2.8.2 of this AGREEMENT, no more than once during any twelve (12) consecutive month period (except to the extent more frequently required in
order to comply with any applicable specific legal or regulatory requirement), MERCK may conduct a COMPLIANCE AUDIT of the facilities of BIOMIRA and its wholly-owned AFFILIATES, and, to the extent
permitted, its non-wholly owned AFFILIATES and subcontractors, at which manufacture, packaging or testing of PRODUCT (whether it is used for clinical or commercial purposes) and its
COMPONENTS is being conducted;

	2.2.8.2
	in
the event of (i) the receipt by BIOMIRA of a "Warning Letter" or a Form 483 (or other equivalent regulatory action) from the FDA relating to the manufacture,
packaging or any other activity performed by BIOMIRA or its AFFILIATES or subcontractors under this AGREEMENT relating to the manufacture or testing of PRODUCT, or (ii) a determination pursuant
to section 2.2.5 of this AGREEMENT that any PRODUCT supplied by BIOMIRA to MERCK under this AGREEMENT does not conform to the applicable SPECIFICATIONS or materially deviates from the
applicable batch records (individually or collectively, an "EVENT"), MERCK shall have the right with respect to each such EVENT to conduct an additional COMPLIANCE AUDIT (such additional COMPLIANCE
AUDIT referred to herein as an "EVENT AUDIT"). With respect to an EVENT AUDIT of the facilities of BIOMIRA, BIOMIRA shall, to the extent applicable, use commercially reasonable efforts to cause its
AFFILIATES and subcontractors to also permit such EVENT AUDIT; 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES. 

8

 

	2.2.8.3
	for
purposes of this AGREEMENT, the term "COMPLIANCE AUDIT" shall mean a review by appropriate representatives of MERCK (not to exceed two (2) in number and who shall, at
BIOMIRA's option, in all circumstances be accompanied by one or more representatives of BIOMIRA and its AFFILIATES) of those portions of BIOMIRA's and its wholly owned AFFILIATES', and, to the extent
permitted, its non-wholly owned AFFILIATES' and subcontractors' facilities at which the manufacture, packaging or testing of PRODUCT and its COMPONENTS is being conducted, for purposes of
reviewing BIOMIRA's, its AFFILIATES' and its subcontractors' procedures and processes used in the manufacture or testing of PRODUCT and its COMPONENTS, including, but not limited to, production and
quality control records related to PRODUCT and its COMPONENTS, and investigations of quality specifically relating to PRODUCT and its COMPONENTS. With respect to such COMPLIANCE AUDIT, BIOMIRA shall
use commercially reasonable efforts to cause its subcontractors to permit such COMPLIANCE AUDIT (including, to the extent reasonable in the circumstances, amending existing and future agreements with
applicable subcontractors to permit MERCK to conduct COMPLIANCE AUDITS pursuant to this section 2.2.8). Any of MERCK's representatives other than MERCK employees conducting any such COMPLIANCE
AUDIT shall, at the reasonable request of BIOMIRA, its AFFILIATES and/or its subcontractors and/or COMPONENT suppliers, enter into an agreement with BIOMIRA, its AFFILIATES and/or its subcontractors
and/or COMPONENT suppliers with respect to confidentiality containing provisions substantially similar to those set forth in article 3 of this AGREEMENT. BIOMIRA and its wholly owned
AFFILIATES, and to the extent applicable and permitted, its non-wholly owned AFFILIATES and subcontractors, shall cooperate with and provide reasonable assistance to MERCK during any such
COMPLIANCE AUDIT. With respect to each facility, MERCK shall complete any such COMPLIANCE AUDIT in five (5) business days. All COMPLIANCE AUDITS shall be at MERCK's expense (including with
respect to representatives of BIOMIRA, except in circumstances where representatives of BIOMIRA are present as part of a regular BIOMIRA audit in which case MERCK shall not be responsible for the
costs and expenses of such representatives of BIOMIRA) and shall take place during normal business hours and with not less than thirty (30) days prior written notice to BIOMIRA and any other
person proposed to be audited. The results of all COMPLIANCE AUDITS and inspections shall be considered CONFIDENTIAL INFORMATION under article 3 of this AGREEMENT; 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES. 

9

 

	2.2.8.4
	in
the event that MERCK is precluded from conducting any audit provided for in this section 2.2.8 of the facilities of a non-wholly-owned AFFILIATE of BIOMIRA
or subcontractor of BIOMIRA, BIOMIRA shall, to the extent it is in a position to do so and upon MERCK's written request, conduct such audit on behalf of MERCK, and MERCK will promptly reimburse
BIOMIRA for all of BIOMIRA's costs and expenses in connection with such requested audit;

	2.2.8.5
	within
thirty (30) days after the completion of any COMPLIANCE AUDIT pursuant to this section 2.2.8, the party conducting the audit shall submit to the other party a
written report outlining its findings and observations from any such COMPLIANCE AUDIT. Within thirty (30) days after receipt of MERCK's report, BIOMIRA shall reply to MERCK, which reply shall,
to the extent applicable, include a timetable for responding to any material findings. If BIOMIRA conducts any audit of any non-wholly owned AFFILIATE of BIOMIRA or subcontractor on behalf
of MERCK pursuant to section 2.2.8.4 of this AGREEMENT, BIOMIRA shall cause, to the extent it is able to do so, such AFFILIATE or subcontractor to respond, to the extent applicable, to any
material findings, taking into account MERCK's comments and concerns.

	2.2.9
	BIOMIRA
and MERCK agree that the responsibility for maintaining the appropriate inventory levels of PRODUCT for purposes of this AGREEMENT and the COLLABORATION AGREEMENT rests with
MERCK. Nevertheless, BIOMIRA shall use commercially reasonable efforts to maintain in inventory following the first LAUNCH of PRODUCT in the TERRITORY one (1) full manufacturing batch of
PRODUCT with customary yields (whatever number of vials such batch produces less the vials (i) used for QC testing and (ii) normal retention) (the "BIOMIRA INVENTORY VIALS"). The parties
acknowledge that the ability to maintain such supply of PRODUCT may be affected by a variety of factors including increased SALES, new regulatory
requirements, Biomira's obligation to replace a batch as set forth in section 2.2.5 above and force majeure. Such PRODUCT inventory shall be rotated based on a first in/first out approach. The
cost of maintaining all the BIOMIRA INVENTORY VIALS shall be borne by BIOMIRA. Subject to the agreement in writing of BIOMIRA and MERCK on the specific terms thereof, MERCK may following the EXECUTION
DATE maintain in inventory such amount of COMPONENTS as is needed for at least two (2) full manufacturing batches of PRODUCT. Such COMPONENTS inventory shall be rotated based on a first
in/first out approach and all costs associated with acquiring and maintaining such inventory shall be borne exclusively by MERCK. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES. 

10

   Section 2.3    Delivery; Title; Risk of Loss  

        BIOMIRA shall transfer PRODUCT to MERCK EX WORKS (INCOTERMS, 2000) facilities of BIOMIRA or its designated AFFILIATES or subcontractors, or such other facilities
as BIOMIRA and MERCK may from time to time agree upon in writing. 

Section 2.4    Import/Export Licenses  

        MERCK shall be responsible for obtaining, at its expense, any import/export licenses required by any governmental authority with respect to PRODUCT from and after
its sale to MERCK pursuant to this AGREEMENT. BIOMIRA agrees, to the extent reasonably required of it, to cooperate with and provide assistance to MERCK in obtaining such licenses and such
documentation required by applicable law and regulation in order to obtain such licenses. If more than five (5) person days in any calendar year of assistance is required to be provided by
BIOMIRA, MERCK shall pay BIOMIRA a per diem fee as agreed upon in writing by BIOMIRA and MERCK. 

Section 2.5    Label Content  

        MERCK shall be responsible for ensuring that the label and product insert for any PRODUCT SOLD in the NA TERRITORY and the ROW TERRITORY shall comply with all
legal, governmental and regulatory requirements. Insofar as it is not contrary to law or regulation in any particular country in the NA TERRITORY and the ROW TERRITORY, the box and package insert, and
the label to the extent that space permits, shall include prominent reference to MERCK as marketer and to BIOMIRA (or its designee) as manufacturer of the PRODUCT. Reference shall also be made on the
vial label/end-user container and package insert, where applicable, to the MPL® trademark (or any replacement or successor trademark). 

Section 2.6    Consideration; Payment Terms  

	2.6.1
	Consideration for Supply Agreement.    In consideration for BIOMIRA agreeing to enter into this AGREEMENT and agreeing to
supply PRODUCT and provide related services to MERCK in the manner set forth in this AGREEMENT, and in addition to the pre LAUNCH milestone payments provided for in section 2.6.2 of this
AGREEMENT and the post LAUNCH milestone payments provided for in section 2.6.3 of this AGREEMENT, MERCK shall:

	2.6.1.1
	[+]

	2.6.1.2
	[+]

	2.6.1.2.1
	[+]

	2.6.1.2.2
	[+]

	2.6.1.2.3
	[+]

	2.6.1.3
	[+]

	2.6.2
	Pre LAUNCH Milestone Payments.    In consideration for BIOMIRA agreeing to enter into this AGREEMENT and agreeing to supply
PRODUCT and provide related services to MERCK in the manner set forth in this AGREEMENT, and in addition to the upfront and other payments provided for in section 2.6.1 of this AGREEMENT and
the post LAUNCH milestone payments provided for in section 2.6.3 of this AGREEMENT, MERCK shall make the following payments to BIOMIRA: 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

11

 

	2.6.2.1
	[+]

	2.6.2.2
	[+]

	2.6.2.2.1
	[+]

	2.6.2.2.2
	[+]

	2.6.2.2.3
	[+]

	2.6.2.2.4
	[+]

	2.6.2.3
	[+]

	2.6.2.3.1
	[+]

	2.6.2.3.2
	[+]

	2.6.2.3.3
	[+]

	2.6.2.3.4
	[+]

	2.6.2.4
	For
clarification, each of the milestone payments of MERCK identified in this section 2.6.2 shall be made only once for the stated milestone triggering event. Any milestone
payments made by MERCK under section 2.6.2 are non-refundable to MERCK.

	2.6.3
	Post LAUNCH Milestone Payments.    In consideration for BIOMIRA agreeing to enter into this AGREEMENT and agreeing to
supply PRODUCT and provide related services to MERCK in the manner set forth in this AGREEMENT, and in addition to the upfront and other payments provided for in section 2.6.1 of this AGREEMENT
and the pre LAUNCH milestone payments provided for in section 2.6.2 of this AGREEMENT, MERCK shall pay to BIOMIRA the following post-LAUNCH milestone payments within
forty-five (45) days of the end of the applicable period specified below:

	2.6.3.1
	[+]

	2.6.3.2
	[+]

	2.6.3.3
	[+]

	2.6.3.4
	[+]

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

12

 

	2.6.3.5
	[+]

	

	For
clarification, each of MERCK's sales milestone payments identified in this section 2.6.3 shall be made only once for the stated sales milestone
triggering event. However, more than one sales milestone may be achieved in a particular calendar year, in which case (if not previously paid) each such sales milestone payments shall be made by MERCK
to BIOMIRA. Any sales milestone payments made by MERCK under this section 2.6.3 are non-refundable to MERCK.

	2.6.4
	The
cost of clinical trial supply of PRODUCT for CLINICAL DEVELOPMENT shall be equal to [+] For commercial SALES, the purchase price payable by MERCK to
BIOMIRA for PRODUCT shall be equal to [+]

	2.6.5
	[+]

	2.6.6
	BIOMIRA
will keep and maintain proper and complete records and books of account in relation to the BIOMIRA COST OF GOODS. BIOMIRA shall at least once in each calendar year during
normal business hours upon thirty (30) days prior written notice from MERCK make those records available for audit by an internationally recognized accounting firm designated by MERCK (except
one to which BIOMIRA shall have objection, acting reasonably, and provided such accounting firm has entered into a confidentiality agreement with the audited party which provides protection for
confidential information which is similar to that provided under article 3 of this AGREEMENT) for the sole purpose of, and BIOMIRA will only be required to disclose information related to,
verifying the BIOMIRA COST OF GOODS. BIOMIRA shall preserve such records made in any calendar year for a period of seven (7) years following the close of that calendar year. Results of any such
examination shall be made available to each of BIOMIRA and MERCK, but all backup documentation and data shall be made available only to such accounting firm for use only on the premises of the audited
party. In the event that such audit discloses that the actual amount of BIOMIRA COST OF GOODS are less than the amount used for purposes of section 2.6.4 and paid by MERCK to BIOMIRA, then
BIOMIRA shall reimburse to MERCK such overpayment. In the event that such audit discloses that the actual amount of BIOMIRA COST OF GOODS are greater than the amount used for purposes of
section 2.6.4 and paid by MERCK to BIOMIRA, then MERCK shall promptly pay to BIOMIRA such underpayment. The cost of such audit shall be borne by MERCK unless such audit discloses that BIOMIRA
COST OF GOODS is more than five percent (5%) less than the amount used for purposes of section 2.6.4 and paid by MERCK to BIOMIRA, in which case BIOMIRA shall be responsible for payment of all
reasonable costs of such audit.

	2.6.7
	Payment Terms.    The purchase price for PRODUCT specified in section 2.6.4 shall be due and payable by MERCK to
BIOMIRA as follows: 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

13

 

	2.6.7.1
	with
respect to the supply of PRODUCT by BIOMIRA to MERCK for CLINICAL DEVELOPMENT:

	2.6.7.1.1
	[+]

	2.6.7.1.2
	[+]

	2.6.7.2
	with
respect to the supply of PRODUCT by BIOMIRA to MERCK for commercial SALE:

	2.6.7.2.1
	[+]

	2.6.7.2.2
	[+]

Section 2.7    Late Payments  

        Any late payments of any nature made under this AGREEMENT shall bear interest, running from the date such payment was due until such payment is made in full, at a
rate per annum equal to the average three (3) month US dollar LIBOR rate (as published from time to time by Reuters) plus one percent (1%). 

Section 2.8    Payments from Germany  

        Unless otherwise agreed to in writing by BIOMIRA and MERCK, MERCK will make all payments and reimbursements to BIOMIRA under this AGREEMENT from Germany. 

Section 2.9    Supply Background  

        BIOMIRA is presently contracting with certain third parties in relation to the supply of PRODUCT. BIOMIRA may continue to use third parties in connection with the
supply of PRODUCT or may assume some or all of such operations itself. To the extent it affects BIOMIRA's obligations to MERCK under this AGREEMENT, BIOMIRA shall (solely for purposes of BIOMIRA's
obligations to MERCK under this AGREEMENT) be responsible for the acts and omissions of the third parties (other than with respect to MERCK and the MERCK SUB-SUPPLIERS and subject to
section 2.11
of this AGREEMENT (including without limitation section 2.11.6)), which it uses in connection with the manufacture and supply of PRODUCT under this AGREEMENT and such acts and omissions shall
be regarded for purposes of this AGREEMENT as the acts and omissions of BIOMIRA. Further, BIOMIRA shall promptly notify MERCK in writing if it receives written notice that any third party supplier
which BIOMIRA is using in connection with the supply of PRODUCT and its COMPONENTS under this AGREEMENT considers BIOMIRA to be in breach of a material provision of any agreement (relating to such
supply of PRODUCT and its COMPONENTS) between BIOMIRA and such third party supplier. BIOMIRA shall not, without the prior written consent of MERCK, which consent shall not be unreasonably withheld,
agree to any change in the specifications for COMPONENTS supplied by such third party supplier to the extent that any such change in specifications for COMPONENTS may affect BIOMIRA's ability to
supply PRODUCT meeting the applicable SPECIFICATIONS under this AGREEMENT. Finally, each of BIOMIRA and MERCK shall, with respect to any "Warning Letter" or Form 483 (or other equivalent
regulatory action) from the FDA received by such party or any AFFILIATE of such party (either in relation to itself or any third party supplier) relating to the manufacture of PRODUCT and its
COMPONENTS under this AGREEMENT, promptly notify the other party and provide the other party with a copy of such "Warning Letter" or Form 483 (or other equivalent regulatory action) from the
FDA or EMEA. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

14

 

Section 2.10    CLINICAL DEVELOPMENT Supply  

        All PRODUCT (as well as placebo) required for CLINICAL DEVELOPMENT in the NA TERRITORY and the ROW TERRITORY shall be supplied by BIOMIRA to MERCK in accordance
with the provisions of this article 2, except to the extent otherwise agreed to in writing by BIOMIRA (or its designated AFFILIATE) and MERCK. All such PRODUCT shall be clearly labelled as
being for clinical trial purposes only and not for commercial SALE. 

Section 2.11    MERCK as Secondary Manufacturer  

	2.11.1
	BIOMIRA
and MERCK acknowledge that sufficient supply of PRODUCT is of importance for the collaboration set forth in the COLLABORATION AGREEMENT, and agree that multiple sourcing is
one of the strategies to reduce the risk of supply shortages. In such regard, MERCK has advised BIOMIRA that MERCK and its AFFILIATE(S) may have manufacturing capacity and manufacturing capabilities
that may be employed for one or more of the necessary steps in the manufacture or testing of PRODUCT. Therefore, subject to the terms and conditions of this Section 2.11, MERCK (directly or
through any of its AFFILIATE(S) and/or third party contract manufacturing organization(s) acceptable to BIOMIRA acting reasonably required by MERCK to act as sub-suppliers to MERCK (the
"MERCK SUB-SUPPLIERS")), shall have the right, at MERCK's option during the term of this AGREEMENT (whether for clinical trial or commercial material), to become a secondary manufacturer
of PRODUCT for BIOMIRA upon such industry standard terms and conditions as BIOMIRA and MERCK, acting reasonably and in good faith, shall agree upon in writing at the relevant time (a "CMO AGREEMENT")
including, without limiting the generality of the foregoing, the following terms and conditions:

	2.11.1.1
	[+]

	2.11.1.2
	MERCK
(and the MERCK SUB-SUPPLIERS) shall fully share with BIOMIRA and its AFFILIATES in a timely manner all inventions, discoveries, improvements, processes,
procedures, data and information in relation to the manufacturing activities undertaken by MERCK (and the MERCK SUB-SUPPLIERS) and shall grant to BIOMIRA and its AFFILIATES the right to
utilize all such rights on a cost-free and non-exclusive basis; and

	2.11.1.3
	BIOMIRA
and its AFFILIATES shall have the right to have their personnel (not to exceed two individuals) monitor the manufacturing activities of MERCK (and, to the extent
permitted, the MERCK SUB-SUPPLIERS) including without limitation attending at facilities of MERCK (and, to the extent permitted, the MERCK SUB-SUPPLIERS). MERCK shall use 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

15

 

	

	commercially
reasonable efforts to cause the MERCK SUB-SUPPLIERS to permit BIOMIRA and its AFFILIATES to have the right to have their personnel
(not to exceed two individuals) monitor the manufacturing activities of the MERCK SUB-SUPPLIERS including without limitation attending at facilities of the MERCK SUB-SUPPLIERS
(including, to the extent reasonable in the circumstances, amending existing and future agreements with the MERCK SUB-SUPPLIERS to permit BIOMIRA and its AFFILIATES to exercise the rights
provided for herein). In the event that BIOMIRA and/or its AFFILIATES are precluded from exercising any of the rights provided for in this section 2.11.1.3 in relation to MERCK
SUB-SUPPLIERS, MERCK shall, to the extent it is in a position to do so, and upon BIOMIRA's written request, exercise such rights on behalf of BIOMIRA and its AFFILIATES.

	2.11.2
	MERCK
(directly or through the MERCK SUB-SUPPLIERS) shall have the right under this section 2.11 to be a secondary manufacturer of PRODUCT for BIOMIRA for up to
(but, for clarity, not more than) [+] percent ([+]%) of BIOMIRA's requirements for PRODUCT. The parties may agree, consistent with the principle of
multiple sourcing, to vary such percentage (for example, to increase MERCK's secondary manufacturing right to more than [+] percent ([+]%) of BIOMIRA's
requirements for PRODUCT), provided that any such variation shall require the unfettered prior written agreement of BIOMIRA and MERCK.

	2.11.3
	The
right of MERCK (directly or through the MERCK SUB-SUPPLIERS) to become a secondary manufacturer of PRODUCT for BIOMIRA shall be subject to any and all contractual
commitments of BIOMIRA with third parties and complying with all applicable legal and regulatory requirements;

	2.11.4
	If
MERCK (and/or any MERCK SUB-SUPPLIER) has with respect to PRODUCT for commercial SALE (i.e., not for CLINICAL DEVELOPMENT):

	2.11.4.1
	[+]

	2.11.4.2
	[+]

	2.11.4.3
	[+]

	2.11.4.4
	[+]

	2.11.4.5
	[+]

	

	then
MERCK (and the MERCK SUB-SUPPLIERS) shall lose its right to be a secondary manufacturer under this section 2.11 until MERCK (and/or,
as applicable, any MERCK SUB-SUPPLIER) regains the ability to achieve a success rate of [+] percent ([+]%) or more and MERCK has
demonstrated to the satisfaction of BIOMIRA, acting reasonably, the ability once again to become a 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

16

 

	

	secondary
manufacturer of PRODUCT for SALE in the NA TERRITORY and ROW TERRITORY in compliance with the provisions of the CMO AGREEMENT, BIOMIRA shall,
subject to then existing third party commitments and provided MERCK fully reimburses BIOMIRA for all substantiated start-up, wind-down and capital expenses necessarily and
specifically incurred by BIOMIRA in order to take over manufacturing of one hundred percent (100%) of MERCK's requirements of PRODUCT (other than those expenses incurred for the manufacturing
activities already performed by BIOMIRA pursuant to this AGREEMENT), unless BIOMIRA, acting reasonably, has the ability to use any such existing third party commitment or capital expense for its
manufacturing responsibilities under this AGREEMENT, and further provided that any necessary transition period shall be two (2) years (unless otherwise agreed in writing by BIOMIRA and MERCK),
permit MERCK to resume such secondary manufacturing activities of PRODUCT. Notwithstanding the foregoing, MERCK agrees to advise BIOMIRA in a timely manner of any material supply difficulties with
respect to PRODUCT experienced by MERCK (and/or the MERCK SUB-SUPPLIERS) so that the parties have an opportunity to discuss such difficulties and possible resolutions thereto at an early
stage.

	2.11.5
	Notwithstanding
any other provision to the contrary in this AGREEMENT (including any QUALITY AGREEMENT) or the COLLABORATION AGREEMENT, all PRODUCT produced by MERCK (and the MERCK
SUB-SUPPLIERS) pursuant to this section 2.11 and/or a CMO AGREEMENT must be transferred to BIOMIRA and/or its designated AFFILIATE under the terms of the applicable CMO AGREEMENT
and none of MERCK or any MERCK SUB-SUPPLIER shall have any right to otherwise sell, use or retain any such PRODUCT.

	2.11.6
	Notwithstanding
any other provision to the contrary in this AGREEMENT (including any QUALITY AGREEMENT) or the COLLABORATION AGREEMENT, MERCK shall not be entitled to rely on any
default by MERCK and/or any MERCK SUB-SUPPLIER under or in respect of any CMO AGREEMENT for purposes of alleging or claiming any default or breach by BIOMIRA of its obligations under this
AGREEMENT (including any QUALITY AGREEMENT) and/or the COLLABORATION AGREEMENT.

	2.11.7
	BIOMIRA
shall use commercially reasonable efforts to transfer to MERCK such PRODUCT manufacturing know-how of BIOMIRA as is necessary for MERCK to perform such
manufacturing activities as may be assigned to MERCK pursuant to this section 2.11 and BIOMIRA and MERCK currently contemplate that the transfer of such manufacturing know-how shall
generally take place in accordance with the following timeline:

	

	[+]

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

17

 

	

	In
connection with such transfer of manufacturing know-how, BIOMIRA shall provide all assistance reasonably required to ensure a smooth
transition of such know-how to MERCK, provided that BIOMIRA and MERCK acknowledge that BIOMIRA's resources required in connection with such transfer obligations are limited and may at
times be required elsewhere. MERCK shall pay BIOMIRA a mutually agreed-upon in writing per diem fee for such assistance on the basis of the amounts set forth in Appendix 4 of the
COLLABORATION AGREEMENT (as such amounts shall be adjusted annually to account for normal wage increases) plus all out-of-pocket expenses. For greater certainty, BIOMIRA and
MERCK agree that any know-how transfer described in this section 2.11.7 (as well as the test assay transfer described in section 2.2.6) shall not require the conclusion of a
separate CMO AGREEMENT but shall be performed in accordance with, solely for the purposes of and subject to the provisions of this AGREEMENT.

	2.11.8
	Any
information received by MERCK, its AFFILIATES and/or third party contract manufacturing organizations (including without limitation MERCK SUB-SUPPLIERS) pursuant to
this section 2.11 shall be subject to the confidentiality provisions of Article 3 of this AGREEMENT. 

Section 2.12    MANUFACTURING LICENSE  

	2.12.1
	License to Make and Have Made in the TERRITORY

	2.12.1.1
	BIOMIRA
hereby grants to MERCK a royalty-free license (or, where applicable, sublicense) under the BIOMIRA TECHNOLOGY and BIOMIRA MANUFACTURING KNOW-HOW
solely to make and have made in the TERRITORY PRODUCT for CLINICAL DEVELOPMENT and SALE by MERCK or its designees pursuant to the COLLABORATION AGREEMENT and in compliance with the licenses, terms and
conditions thereof (the "MANUFACTURING LICENSE"); provided, however, that MERCK may not practice the MANUFACTURING LICENSE until such time, if ever, as,
with respect to PRODUCT for commercial SALE (i.e., not for CLINICAL DEVELOPMENT):

	2.12.1.1.1
	[+]

	2.12.1.1.2
	[+]

	2.12.1.1.3
	[+]

	2.12.1.1.4
	[+]

	2.12.1.1.5
	[+]

	

	and
BIOMIRA does not provide to MERCK within the twenty (20) day period immediately following BIOMIRA becoming aware of the occurrence of any such
event a reasonable plan of corrective action, then, if MERCK desires to practice the MANUFACTURING LICENSE with respect to PRODUCT, MERCK shall notify BIOMIRA in writing of such desire within 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

18

 

	

	the
next fifteen (15) days following the expiry of such twenty (20) day period. The parties may from time to time agree in writing to modify
the above-referenced conditions with respect to the commencement of MERCK's MANUFACTURING LICENSE.

	2.12.1.2
	Notwithstanding
the foregoing, BIOMIRA agrees to advise MERCK in a timely manner of any material supply difficulties with respect to PRODUCT experienced by BIOMIRA so that the
parties have an opportunity to discuss such difficulties and possible resolutions thereto at an early stage with a view to avoiding the application of the MANUFACTURING LICENSE in relation to PRODUCT.

	2.12.1.3
	[+]

	2.12.1.4
	During
any period in which MERCK is entitled under this section 2.12 to practice the MANUFACTURING LICENSE with respect to PRODUCT, MERCK shall be responsible for all
aspects of the manufacture and supply of PRODUCT and, as a result, BIOMIRA shall, notwithstanding any provision to the contrary in this AGREEMENT (including any QUALITY AGREEMENT), be relieved from
all obligations under this AGREEMENT (including any QUALITY AGREEMENT) with respect to such manufacture and supply including without limitation any liability in respect thereof to MERCK or any third
party, except in relation to PRODUCT manufactured and supplied by BIOMIRA to MERCK prior to the commencement of any such period and, subject to MERCK's compliance with section 2.12.1.3, in
relation to third party contractual obligations to BIOMIRA's suppliers and subcontractors arising prior to MERCK's assumption of such obligations; and

	2.12.1.5
	only
modify the label of PRODUCT to the extent required by the applicable regulatory authority.

	2.12.1.6
	If
at any time after MERCK begins to practice the MANUFACTURING LICENSE with respect to PRODUCT, BIOMIRA has demonstrated to the satisfaction of MERCK, acting 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

19

 

	

	reasonably,
the ability once again to manufacture PRODUCT for SALE in the NA TERRITORY and ROW TERRITORY in compliance with the provisions of this
AGREEMENT, MERCK shall, subject to then existing third party commitments and provided BIOMIRA fully reimburses MERCK for all substantiated start-up, wind-down and capital
expenses necessarily and specifically incurred by MERCK in order to practice the MANUFACTURING LICENSE (other than the manufacturing activities already performed by or on behalf of MERCK pursuant to
section 2.11), unless MERCK, acting reasonably, has the ability to use any such existing third party commitment or capital expense for purposes of being a secondary manufacturer as set forth in
section 2.11 of this AGREEMENT, and further provided that any necessary transition period shall be two (2) years (unless otherwise agreed by the PARTIES), permit BIOMIRA to resume such
manufacturing activities of PRODUCT for SALE in the NA TERRITORY and ROW TERRITORY. Upon such resumption by BIOMIRA, MERCK will no longer be entitled to practice the MANUFACTURING LICENSE with respect
to PRODUCT in the TERRITORY (except to the limited extent required to enable MERCK to comply with then existing third party commitments regarding manufacture of PRODUCT) until such time as the
conditions described in section 2.12.1.1 above recur and MERCK is thereby entitled to again practice the MANUFACTURING LICENSE. BIOMIRA's right with respect to PRODUCT to resume manufacturing
activities shall only apply once.

	2.12.2
	MERCK Cost of Manufacture.    MERCK shall be responsible for of all its costs of manufacture of PRODUCT under
section 2.12, including all fixed and variable costs. However, notwithstanding any other provision to the contrary in this AGREEMENT (including any QUALITY AGREEMENT) or the COLLABORATION
AGREEMENT, MERCK shall only be entitled to deduct under section 6.3 of the COLLABORATION AGREEMENT (on a per DOSE basis) the lesser of (i) MERCK's actual costs of manufacture and
(ii) the amount that BIOMIRA was paying to a third party CMO at the time that MERCK became entitled to practice the MANUFACTURING LICENSE under this section 2.12. 

Section 2.13    Protection in Bankruptcy  

        The rights and licenses granted to MERCK by BIOMIRA pursuant to section 2.12 are, and shall be deemed to be, for purposes of applicable bankruptcy law
(including section 365(n) of the United States Bankruptcy Code), licenses of rights to "intellectual property" (including as such term is defined under section 101(35A) of the United
States Bankruptcy Code, as amended from time to time) for purposes of applicable bankruptcy law (including section 365(n) of the United States Bankruptcy Code). The parties agree that MERCK, as
a contingent licensee of such rights under this AGREEMENT, shall retain and may fully exercise all of its rights and elections under such applicable bankruptcy law, including but not limited to
MERCK's rights to continue to exercise all rights contingently licensed hereunder. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

20

   Section 2.14    CMC Development Activities  

        BIOMIRA and MERCK acknowledge that certain CMC development activities (such as, without limitation, characterization, studies for forced degradation, freeze/thaw
stability, and in-use tests as well as the development of a large scale manufacturing process) need to be completed before submission of a BLA for the PRODUCT in accordance with applicable
guidelines and any CMC plan approved in accordance with section 3.2.2 of the COLLABORATION AGREEMENT. All as contemplated by and within the parameters set forth in section 3.2.4 of the
COLLABORATION AGREEMENT, the Manufacturing/CMC Project Team shall (i) discuss in good faith and agree upon what activities fall under BIOMIRA's manufacturing responsibilities (i.e. as the
manufacturer of PRODUCT that needs MARKET APPROVAL prior to first commercial sale) and (ii) determine defined work packages to be performed by either of the parties, including relevant
timelines. To the extent that these activities form part of BIOMIRA's manufacturing responsibilities under this AGREEMENT, MERCK may, if BIOMIRA so requests in writing, support BIOMIRA in such
activities by way of performing some of such required CMC development activities at BIOMIRA's cost and expense (such costs and expenses to be agreed upon in writing by BIOMIRA and MERCK prior to the
commencement of any such work). Upon BIOMIRA's request to MERCK and agreement in writing between the parties on the scope of work (and a budget related thereto) to be undertaken by MERCK in relation
to such CMC development activities, MERCK shall assist BIOMIRA by way of performing the activities allocated to MERCK by BIOMIRA in a timely and professional manner. 

Section 2.15    Payment of Taxes  

        Each of BIOMIRA and MERCK shall be responsible for any and all taxes and other similar levies or charges properly assessed against payments received by such party
from the other party under this AGREEMENT. If applicable laws or regulations require that taxes be withheld on such payments, the withholding party will in a timely manner notify the other party in
writing specifying the details thereof and shall: 

	2.15.1
	deduct
those taxes from the amount of such payment due to the receiving party,

	2.15.2
	pay
the taxes to the proper taxing authority in a timely manner, and

	2.15.3
	send
proof of payment to the receiving party within sixty (60) days following that payment. 

        The
parties agree to cooperate to reduce the amount of any such deductions and to obtain the benefit of any tax treaty with respect to such deductions. Further, the withholding party
shall cooperate with the receiving party in obtaining for the receiving party a credit or refund for any such taxes, levies or charges. Neither party shall be required under this concluding paragraph
of section 2.13 to act in a manner which is financially detrimental from a taxation perspective to such party. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

21

 

Section 2.16    No Samples  

        Unless BIOMIRA and MERCK otherwise agree in writing, no samples of PRODUCT shall be made available by MERCK to any END USERS. 

ARTICLE 3

CONFIDENTIALITY  

Section 3.1    Definition  

        CONFIDENTIAL INFORMATION is any and all information of a confidential nature including without limitation manufacturing plans, any data and/or information
generated under this AGREEMENT, any and all data and/or other information related to the BIOMIRA MANUFACTURING KNOW-HOW which is proprietary to the disclosing party and not generally
known, and technological information not limited to compound(s), composition(s), formulation(s) and/or, manufacturing information, and including business information not limited to commercial
forecasts, plans, programs, customers, assets, financial projections, and costs. 

Section 3.2    Obligations  

        Each party agrees to hold all of the other party's CONFIDENTIAL INFORMATION received or generated in connection with this AGREEMENT (either prior to, on, or after
the EFFECTIVE DATE) in confidence and neither disclose it to any third party nor allow any third party access to it nor use it for any purpose other than as specified by this AGREEMENT. Disclosure by
a receiving party of CONFIDENTIAL INFORMATION of the other party shall only be made to such of its directors, officers, employees, agents and consultants whose duties require such disclosure and then
only if the persons to whom such CONFIDENTIAL INFORMATION is disclosed are bound by appropriate confidentiality undertakings. The above notwithstanding, each of MERCK and BIOMIRA may disclose
CONFIDENTIAL INFORMATION of the other party to their respective AFFILIATES or distributors on a "need-to-know" basis provided such persons are bound by like terms of
confidentiality as those stated herein. 

Section 3.3    Exceptions  

        These obligations of non-disclosure and non-use shall not apply to CONFIDENTIAL INFORMATION which: 

	3.3.1
	was,
at the time of disclosure, in the possession of the receiving party (as evidenced by its written records) and was not previously acquired from or on behalf of the disclosing
party on a confidential basis,

	3.3.2
	was
in the public domain prior to disclosure, or became, after disclosure, publicly known through no fault of the receiving party or any person to whom the receiving party directly
or indirectly provided such CONFIDENTIAL INFORMATION,

	3.3.3
	was
received from a third party who rightfully made such disclosure,

	3.3.4
	was
approved for use or release by written authorization from the disclosing party prior to such use or release by the receiving party,

	3.3.5
	is
required to be disclosed by operation of law, governmental regulation or court order provided the receiving party gives the disclosing party written notice of such required
disclosure prior to making such disclosure, and the receiving party uses all reasonable effort to cooperate in securing confidential protection for such information; or 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

22

 

	3.3.6
	is
required to be disclosed to any governmental authority or regulatory authority to the extent that such disclosure is reasonably necessary to obtain authorizations to conduct a
clinical trial with and to market commercially PRODUCTS, provided the disclosing party is otherwise entitled to engage in such activities under this AGREEMENT. 

Any
specific CONFIDENTIAL INFORMATION shall not be deemed to fall within 3.3.1, 3.3.2, 3.3.3, 3.3.4, 3.3.5 or 3.3.6 above merely because it falls within the scope of more general information within
one of these exceptions. 

Section 3.4    Term of Confidentiality  

        These obligations of confidentiality and nonuse are binding throughout the duration of this AGREEMENT and shall remain in force for a period of ten
(10) years from the date of the expiration or termination of this AGREEMENT. 

Section 3.5    Return of Information  

        Upon termination and upon request from the disclosing party, the receiving party agrees to promptly return all originals and copies of CONFIDENTIAL INFORMATION
received, as well as permanently delete all electronically or otherwise stored CONFIDENTIAL INFORMATION from all systems containing such CONFIDENTIAL INFORMATION, except that one copy may be retained
by legal counsel solely as a measure of the receiving party's obligations under this AGREEMENT. 

Section 3.6    Nature of Transaction  

	3.6.1
	Confidentiality.    Neither party may disclose any information regarding the nature and/or occurrence of this transaction,
or the nature and/or occurrence of any event or information occurring as a result of this transaction without the prior written consent of the other party (such consent not to be unreasonably
withheld), except that each of MERCK and BIOMIRA may disclose such information to their respective AFFILIATES that are under like terms of confidentiality as those stated herein without such consent
and any such information that is required by law or any applicable regulatory authority to be disclosed (to the extent required to be disclosed). Where practicable, prior to any required submission of
the terms of this transaction to any governmental agency or authority, the disclosing party shall provide the other party with a copy of such submission including, without limitation, identification
of any portions of this Agreement which the disclosing party intends to redact or intends to request the governmental agency or authority to redact, so that the other party may review and comment on
any such proposed submission. The disclosing party shall initially redact financial terms (and such other material terms as are appropriate in the circumstances) and will use commercially reasonable
efforts to obtain the concurrence of the governmental agency or authority to such redaction of financial and other material terms. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

23

 

	3.6.2
	Press Release.    The parties shall agree on a press release to announce the execution of this Agreement, and on a Question
and Answer ("Q&A") outline for use in responding to inquiries about this AGREEMENT. With respect to future press releases or other public statements relating to the subject matter of this AGREEMENT,
including, but not limited to, webcast materials, press kits and Q&A's, except as required by law or any applicable regulatory authority (and even then to the extent practicable) and except with
respect to information already in the public domain or previously approved by the other party, BIOMIRA and MERCK shall each provide to the other party a copy of any proposed press release and the
other party shall provide any comments with respect thereto within the same period of time (which shall be specified, but shall not be less than twenty four (24) hours) as the party proposing
to issue such press release has permitted for its own internal review. If no comments are received by the issuing party within the permitted review period, the press release in question shall be
deemed to have been approved by the other party. If comments are received by the issuing party within the permitted review period, then the issuing party shall seriously and in good faith consider
such comments and, to the extent such comments are not incorporated in such press release, only the minimum legally or regulatorily required disclosure shall be made with respect to such matters. 

ARTICLE 4

REPRESENTATIONS AND WARRANTIES OF BIOMIRA  

Section 4.1    Representations and Warranties of BIOMIRA  

        All as specified in section 2.2.3 of this AGREEMENT and otherwise subject to the provisions of article 2 of this AGREEMENT, BIOMIRA represents and
warrants that all PRODUCT purchased under this AGREEMENT by MERCK from BIOMIRA shall conform at the time of delivery by BIOMIRA to MERCK to the applicable SPECIFICATIONS, shall have been manufactured
in accordance with cGMP and all applicable laws and regulations in the country of manufacture (and, if MERCK has in a timely manner informed BIOMIRA in writing thereof, the specific applicable laws
and regulations of the United States of America and the European Union and, if BIOMIRA agrees in writing, any other country in the ROW TERRITORY), and no such PRODUCT shall, at the time of delivery by
BIOMIRA to MERCK, be adulterated or misbranded within the meaning of the United States Food, Drug and Cosmetics Act and/or the  Public Health Service Act,
to the extent applicable, be an article which may not be introduced into interstate commerce under section 505 of the  United States Food, Drug and Cosmetics Act and/or section 351 of the
Public Health Service Act.
 

ARTICLE 5

TERM AND TERMINATION  

Section 5.1    Term and Expiration  

	5.1.1
	This
Agreement shall be effective as of the EFFECTIVE DATE and, unless terminated earlier pursuant to this article 5, this AGREEMENT shall expire with respect to the NA
TERRITORY or the ROW TERRITORY, as the case may be, upon the expiration of the COLLABORATION AGREEMENT with respect to such territory (i.e., the NA TERRITORY or the ROW TERRITORY). 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

24

 

	5.1.2
	Upon
the expiration or termination (other than as a result of a breach of this AGREEMENT and/or the COLLABORATION AGREEMENT by MERCK, or section 5.2.3 of this AGREEMENT or
section 11.2.4 of the COLLABORATION AGREEMENT becoming applicable to MERCK, or the invocation by MERCK of section 11.2.5 of the COLLABORATION AGREEMENT) of this AGREEMENT pursuant to
section 5.1.1:

	5.1.2.1
	with
respect to PRODUCT in relation to the NA TERRITORY or all of the ROW TERRITORY, as the case may be, BIOMIRA and MERCK agree, in circumstances where there remains a market for
PRODUCT in such country, to undertake bona fide good faith negotiations to conclude in a timely manner a revised supply agreement pursuant to which BIOMIRA would continue to supply PRODUCT to MERCK
for SALE in such country; and

	5.1.2.2
	with
respect to PRODUCT in relation to the NA TERRITORY or all of the ROW TERRITORY, as the case may be, MERCK shall have a fully paid up, royalty free, non-exclusive
license under the BIOMIRA TECHNOLOGY and the BIOMIRA MANUFACTURING KNOW-HOW to make and have made PRODUCT in such territory, subject, to the extent applicable, to compliance with the THIRD
PARTY LICENSES (including the payment of any and all royalties and other amounts required to be paid thereunder). 

Section 5.2    Early Termination  

        This AGREEMENT may be terminated as follows: 

	5.2.1
	by
mutual written agreement of BIOMIRA and MERCK, effective as of the time specified in such written agreement;

	5.2.2
	by
either party, upon any breach of this AGREEMENT by the other party of any obligation to make payments required hereunder, which failure to make payment is not the subject of a
legitimate, good faith dispute between the parties, provided, however, that the party alleging such breach must first give the other party written
notice thereof, which notice must identify the breach in reasonable detail and that the party giving such notice views such alleged breach as a basis for terminating this AGREEMENT under this
section 5.2.2 and the party receiving such notice must have failed to cure such alleged breach within forty-five (45) days after receipt of such notice;

	5.2.3
	by
either party, in the event that the other party institutes any proceedings under any 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

25

 

statute
or otherwise relating to insolvency or bankruptcy, or should any such proceedings under any such statute or otherwise be instituted against the other party and not be dismissed or vacated
within ninety (90) days of the date that the other party has actual knowledge of the commencement of such proceedings; or 

	5.2.4
	by
either party, upon the termination in its entirety of the COLLABORATION AGREEMENT. 

Section 5.3    Continuing Liability  

        Termination of this AGREEMENT for any reason shall not release any party from any liability, obligation or agreement which has already accrued nor affect the
survival of any provision hereof which is expressly stated to survive such termination. Termination of this AGREEMENT for any reason shall not constitute a waiver or release of, or otherwise be deemed
to prejudice or adversely affect, any rights, remedies or claims, whether for damages or otherwise, which a party may have hereunder or which may arise out of or in connection with such termination. 

Section 5.4    Continuing Obligation to Make Payments  

        Notwithstanding any other provision to the contrary in this AGREEMENT, on the termination or expiration of this AGREEMENT for any reason, MERCK shall continue to
be obligated for so long as the COLLABORATION AGREEMENT is in force and effect to make the payments to BIOMIRA provided for in sections 2.6.1, 2.6.2 and 2.6.3 in accordance with the terms of sections
2.6, 2.7 and 2.8. 

ARTICLE 6

INDEMNIFICATION  

Section 6.1    Indemnification by BIOMIRA  

        Subject to the terms and conditions of this AGREEMENT, BIOMIRA shall indemnify and hold MERCK (and any affiliated corporation and their respective officers,
directors, shareholders, employees and agents) (collectively, the "MERCK INDEMNITEES"), free and harmless from any and all claims, demands, liabilities, losses, actions or causes of actions, and any
and all expenses associated therewith (including, without limiting the generality of the foregoing, reasonable defense costs and attorney's fees), arising out of or in connection with, or that are the
result of, or are otherwise related to: (i) actions and proceedings brought by any regulatory or other authority against any of the MERCK INDEMNITEES concerning PRODUCT, for or on account of
the alleged unapproved or unauthorized introduction by BIOMIRA, its AFFILIATES or their respective agents of PRODUCT in interstate or intrastate commerce anywhere in the world; (ii) any claim,
complaint, suit, proceeding or cause of action against any of the MERCK INDEMNITEES alleging physical injury, including death as a result of the acts or omissions of BIOMIRA, its AFFILIATES or their
respective employees and agents, except to the extent attributable to any one or more of the MERCK INDEMNITEES; (iii) BIOMIRA's, its AFFILIATES' or their respective agents'
non-compliance with any applicable laws or regulations, except to the extent attributable to any one or more of the MERCK INDEMNITEES; (iv) any failure of BIOMIRA to perform, in
whole or in part, any of its obligations hereunder, except to the extent attributable to any one or more of the MERCK INDEMNITEES; (v) 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

26

 

BIOMIRA's
manufacture of PRODUCT, except to the extent attributable to any one or more of the MERCK INDEMNITEES; or (vi) any breach by BIOMIRA of any of its representations or warranties under
this AGREEMENT. 

Section 6.2    Indemnification by MERCK  

        Subject to the terms and conditions of this AGREEMENT, MERCK shall indemnify and hold BIOMIRA (and any affiliated corporation and their respective officers,
directors, shareholders, employees and agents) (the "BIOMIRA INDEMNITEES"), free and harmless from any and all claims, demands, liabilities, losses, actions or causes of actions, and any and all
expenses associated therewith (including, without limiting the generality of the foregoing, reasonable defenses costs and attorney's fees), arising out of or in connection with, or that are the result
of, or are otherwise related to:
(i) actions and proceedings brought by any regulatory authority against any of the BIOMIRA INDEMNITEES concerning PRODUCT, for or on account of the alleged unapproved or unauthorized
introduction by MERCK, its AFFILIATES or their respective distributors, sublicensees and agents of PRODUCT in interstate or intrastate commerce anywhere in the world; (ii) any claim, complaint,
suit, proceeding or cause of action against any of the BIOMIRA INDEMNITEES alleging physical injury, including death as a result of the acts or omissions of MERCK, its AFFILIATES or their respective
employees, distributors, sublicensees and agents, except to the extent attributable to any one or more of the BIOMIRA INDEMNITEES; (iii) MERCK's, its AFFILIATES' or their respective
distributors', sublicensees' or agents' non-compliance with any applicable laws or regulations, except to the extent attributable to any one or more of the BIOMIRA INDEMNITEES;
(iv) any failure of MERCK to perform, in whole or in part, any of its obligations hereunder, except to the extent attributable to any one or more of the BIOMIRA INDEMNITEES; (v) the
manufacture of PRODUCT by or on behalf of MERCK (including without limitation MERCK SUB-SUPPLIERS), except to the extent attributable to any one or more of the BIOMIRA INDEMNITEES; or
(vi) MERCK's, its AFFILIATES' or their respective distributors', sublicensees' or agents' marketing and/or SALE of PRODUCT, except to the extent attributable to any one or more of the BIOMIRA
INDEMNITEES. 

Section 6.3    Procedure  

        The indemnified party shall give prompt written notice to the indemnifying party(ies) of any suits, claims or demands by third parties or the indemnified party
which may give rise to any loss for which indemnification may be required under this article 6; provided, however, that failure to give such
notice shall not impair the obligation of the indemnifying party to provide indemnification hereunder except if and to the extent that such failure materially impairs the ability of the indemnifying
party to defend the applicable suit, claim or demand. The indemnifying party shall be entitled to assume the defense and control of any suit, claim or demand of any third party at its own cost and
expense; provided, however, that the other party shall have the right to be represented by its own counsel at its own cost in such matters. In the event
that the indemnifying party shall decline to assume control of any such suit, claim or demand, the party entitled to indemnification shall be entitled to assume such control, conduct the defense of,
and settle such suit, claim or action, all at the sole cost and expense of the indemnifying party. Neither the indemnifying party nor the indemnified party shall settle or dispose of any such matter
in any manner which would adversely impact the rights or interests of the other party without the prior written consent of the indemnified party, which shall not be unreasonably withheld. Each party
shall cooperate with the other party and its counsel in the course of the defense of any such suit, claim or demand, such cooperation to include using reasonable efforts to provide or make available
documents, information and witnesses. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

27

 
ARTICLE 7

MISCELLANEOUS  

Section 7.1    Force Majeure  

        Any delay in the performance of any of the obligations of either party (except for the payment of money) shall not be considered a breach of this AGREEMENT and
the time required for performance shall be extended for a period equal to the period of such delay, provided that such delay has been caused by or is the result of (including without limitation in
relation to third party contractors and suppliers) any act of God, acts of the public enemy; insurrections; riots; embargoes; labor disputes such as strikes, lockouts or boycotts; fires; explosions;
floods; earthquakes; mudslides; or other unforeseeable causes beyond the control of the party so affected. The party so affected shall give prompt notice to the other party of such cause, and shall
take whatever reasonable steps are necessary to relieve the effect of such cause as rapidly as reasonable. 

Section 7.2    Independent Contractor  

        Execution of each party's responsibilities under this AGREEMENT is solely under the direction and control of each respective party as an independent contractor,
and not as an employee of the other party. 

Section 7.3    Survival  

        The following articles, sections and section shall survive expiration or termination of this AGREEMENT: article 3, article 6, sections 5.3, 5.4 and
7.9. 

Section 7.4    Notice  

        Whenever any notice is to be given hereunder, it shall be in writing and shall be deemed received on the day delivered, if delivered by courier on a business day,
or if sent by first-class certified or registered mail, postage prepaid, to the following addresses: 

	 	BIOMIRA:
	 	 	Biomira International Inc.

Suite No. 1, "Evergreen House"

Belleville, St. Michael, Barbados

West Indies

Attention: The Secretary

Facsimile: (246) 288-8932
	

 	

with a copy to:
	 	 	Biomira Inc.

2011 - 94 Street

Edmonton, Alberta T6N 1H1

Canada

Attention: President

Facsimile: (780) 450-4772

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

28

 

	 	MERCK:
	 	 	Merck KGaA Frankfurter Strasse 250

D-64293 Darmstadt

Germany

Attention: Corporate Legal Department

Facsimile: +49-6151-72-2373

Section 7.5    Waivers  

        No waiver of any term, provision, or condition of this AGREEMENT, whether by conduct or otherwise, in any one or more instances, shall be deemed to be construed
as a further or continuing waiver of any such term, provision, or condition of this AGREEMENT unless reduced to writing signed by an authorized representative of each party. 

Section 7.6    Applicable Law  

        This Agreement shall be construed under the substantive laws of England, without reference to its conflicts of laws provisions. 

Section 7.7    Dispute Resolution  

        Should any dispute arise between the parties concerning this AGREEMENT, the parties agree to first attempt to resolve the dispute in good faith. If within fifteen
(15) days of one party providing written notice of such dispute to the other party such dispute is not resolved, then the parties agree to continue to attempt to resolve the dispute in good
faith through meetings between a member of MERCK's Pharmaceutical Executive Management Board and the President of BIOMIRA before resorting to any other forum for a remedy. If resolution of the dispute
is not reached between the Presidents within twenty (20) days of either party submitting such dispute in writing to the Presidents, then the parties shall within the next following fifteen
(15) day period initiate binding arbitration in London, England under the rules of the International Chamber of Commerce. The party desiring arbitration shall nominate one (1) arbitrator
and shall notify the other party in writing of such nomination. Such other party shall, within ten (10) days after receiving such notice, nominate an arbitrator and the two
(2) arbitrators shall select a third arbitrator of the arbitration tribunal to act
jointly with them. The parties will act reasonably and in good faith to select arbitrators who are objective and who are suitably qualified by education or professional experience to deal with the
matters which are the subject of the arbitration. 

Section 7.8    Assignment  

        The parties agree that this AGREEMENT is personal in nature and, except for transfer by BIOMIRA to any of BIOMIRA's AFFILIATES, this AGREEMENT may not be assigned
or otherwise transferred, nor may any right or obligations hereunder be assigned or transferred directly or indirectly by either party, whether voluntary, by operation of law or otherwise, without the
written consent of the other party, such consent not to be unreasonably withheld. In connection with BIOMIRA determining whether to consent to an assignment, the parties agree that BIOMIRA shall be
deemed to be acting reasonably if it withholds its consent in circumstances where the proposed assignee is not a corporation of equal or greater financial resources, marketing strength and expertise
(including in the cancer area), and stature in the pharmaceutical industry as MERCK. Any purported assignment in violation of this section 7.8 shall be void. Notwithstanding the foregoing,
either party may, without such consent, assign or novate this 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

29

 

AGREEMENT
and its rights and obligations hereunder in connection with the transfer or sale of all or substantially all of its business, through merger, consolidation or change in control or similar
transaction after first giving the other party written notice of such event. Any permitted assignee shall assume all obligations of the assignor under this AGREEMENT. 

Section 7.9    Limitation  

        Notwithstanding any other provision to the contrary in this AGREEMENT, other than with respect to applicable third party product liability and patent infringement
claims, the maximum aggregate liability of BIOMIRA under this AGREEMENT (including any QUALITY AGREEMENT) and the COLLABORATION AGREEMENT shall not exceed the amounts paid by MERCK to BIOMIRA up to
the time in question under this AGREEMENT and the COLLABORATION AGREEMENT
(including, for greater certainty, payments by MERCK under this AGREEMENT and the COLLABORATION AGREEMENT with respect to shared costs, equity purchases and milestones).[+] 

Section 7.10    Severability  

        If any provision of this AGREEMENT is held to be illegal or unenforceable, that provision shall be limited to the minimum extent necessary or, if necessary,
eliminated, so that this AGREEMENT shall otherwise remain enforceable and in full force and effect. 

Section 7.11    Integration Clause  

        Other than the COLLABORATION AGREEMENT, this AGREEMENT is the sole agreement with respect to the subject matter hereof, and supersedes all proposals,
negotiations, conversations, discussions, agreements and/or representations, whether oral or written, including any industry custom or past dealing between the parties relating to the subject matter
of this AGREEMENT. The parties agree that any and all obligations between the parties that are outside the terms of this AGREEMENT and that relate to the subject matter of this AGREEMENT that preceded
the EFFECTIVE DATE of this AGREEMENT have been satisfactorily executed or are null and void. 

Section 7.12 U.S.    Dollars  

        Unless otherwise provided, any reference in this AGREEMENT to dollars shall be to U.S. dollars. 

Section 7.13    Amendment of Agreement  

        No change, modification, extension, termination, waiver or other amendment of this AGREEMENT or any of the provisions contained herein, shall be valid unless made
in writing and signed by a duly authorized representative of each party. 

Section 7.14    Third Parties  

        A person who is not a party to this AGREEMENT has no rights under the Contracts (Rights of Third Parties) Act 1999 to enforce any term of this AGREEMENT. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

30

 

Section 7.15    No Further Representations or Warranties  

        Each party acknowledges that it has not relied on or been induced to enter this AGREEMENT by a representation or warranty other than those expressly set out in
this AGREEMENT. A party is not liable to the other party for a representation or warranty that is not set out in this AGREEMENT, including any warranty implied by statute. 

Section 7.16    Counterparts  

        This Agreement may be executed in several counterparts, each of which when so executed shall be deemed to be an original and shall have the same force and effect
as an original but such counterparts together shall constitute but one and the same instrument. 

        This
amended and restated agreement is agreed to and accepted by: 

	MERCK KGaA	 	BIOMIRA INTERNATIONAL INC.
	

By:	
 	

 	
 	

By:	
 	

 
	 	 	
	 	 	 	

	

Title:	
 	

 	
 	

Title:	
 	

 
	 	 	
	 	 	 	

	AND	 	 	 	 	 	 
	By:	 	 	 	 	 	 
	 	 	
	 	 	 	 
	

 	
 	

 	
 	

[IN DUPLICATE]
	

Title:	
 	

 	
 	

 	
 	

 
	 	 	
	 	 	 	 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

31

 
 

Schedule 1    
    
    SPECIFICATIONS    
    

1)    Stimuvax (BLP25 Liposome Vaccine), 300 μg:  

[+] 

2)    Stimuvax Placebo:  

[+] 

3)    MPL® (Monophosphoryl lipid A)  

[+] 

4)    BLP25 Lipopeptide  

PN-08-0005 

[+] 

5)    Cholesterol  

PN-01-0099 

[+]

6)    DMPG  

PN-01-0101

[+] 

7)    DPPC  

PN-01-0100 

[+] 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

 
 

Schedule 2    
    
    QUALITY AGREEMENT (Clinical)    
    

[+] 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

 
 

Schedule 3    
    
    QUALITY AGREEMENT (Commercial)    
    

[to be attached when completed by the parties]

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

 
 

Schedule 4    
    
    CERTIFICATE OF ANALYSIS    
    

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

CERTIFICATE OF ANALYSIS  

Product: BLP25 Liposome Vaccine Placebo, Unlabelled Vials  

[+]

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

CERTIFICATE OF ANALYSIS  

Product: BLP25 Liposome Vaccine, Lyophilized Product, Unlabelled Vials  

[+]

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

QuickLinks

AMENDED AND RESTATED SUPPLY AGREEMENT (2006)

Schedule 1 SPECIFICATIONS

Schedule 2 QUALITY AGREEMENT (Clinical)

Schedule 3 QUALITY AGREEMENT (Commercial)

Schedule 4 CERTIFICATE OF ANALYSISQuickLinks
 -- Click here to rapidly navigate through this document
  

Exhibit 10.25  

 
  BIOMIRA SEVERANCE AGREEMENT    
    

        SEVERANCE AGREEMENT made as of the 21st day of March, 2006. 

        BETWEEN:

BIOMIRA INC., a corporation,

incorporated under the laws of Canada 

THE
COMPANY 

-and
-
 Rao Koganty an employee

of the Company or one of its Subsidiaries or

an entity controlled by the Company 

OF
THE SECOND PART 

        WHEREAS the Company has implemented an Executive Severance Plan in relation to the termination of employment of Employee-Officers of the
Company in the following situations: 

	A)
	In
the regular course of events (i.e. other than in the event of a "Change of Control"), 

and  B)    In
the event of a "Change of Control". 

        The
following terms of severance will apply. These are based on an agreement that you will not, without first having obtained the prior written consent of the Company, either solely or
in partnership, or jointly in conjunction with any person or persons, firm, association, syndicate or corporation, whether as principal, agent, shareholder, employee or in any manner whatsoever, carry
on, be engaged in, employed, concerned with or interested in any business, employment, activity, operation or position whatsoever similar to the present position occupied by you, or at any time
carried on by the Company during your employment with the Company, with a direct competitor of the Company for a period of two (2) years from the date of severance. For purposes of this
Agreement, direct competitors include companies or divisions of companies that have, as their primary technology platform, the development of cancer immunotherapies or therapeutic cancer vaccines or
technologies. 

        You
further agree that you will not recruit Company employees for a period of two (2) years from the date of severance. 

        If
you are paid any amounts under this Agreement and you contravene any of the conditions contained herein, you will be required to repay, with interest, any applicable amounts paid, and
such amounts may be collected by the Company as a debt owing from you. 

	1.
	Severance

 
	A.
	In the Regular Course of Events  

If
in the regular course of events the Company should deliver to you written notice that your services hereunder will no longer be required, the Company will pay or cause you to be paid (a) one
and one-half (1.5) times the amount of your annual salary in effect at the time such notice is given, (b) the annual bonus amount, if any, paid to you in relation to the immediately
preceding fiscal year, and (c) an additional sum equal to 20% of your annual salary then in effect in lieu of any further benefits under this agreement, except to the extent these would already
have accrued or been earned by you under the Company's retirement or option plans (all benefits cease as of the date of severance). Such monies will be paid as set out below upon the execution by you
of a Release acceptable to the Company. The sum of 

1

 

these
amounts (a), (b) and (c) shall be paid in equal monthly installments over eighteen (18) months. 

If
notice is given to you that your services hereunder will no longer be required, you hereby resign forthwith from any and all offices and directorships held by you with the Company and release the
Company and its officers from any liability arising out of the employment relationship or the termination of the employment relationship. The "date of severance" will be the date of the written notice
or such date as specified therein. 

In
addition, should the Company, alter the scope of your duties hereunder, in such manner that in result you suffer what would constitute a demotion resulting in constructive dismissal (in the context
of an employer-employee relationship), you shall be entitled to treat this as notice of constructive termination of your services hereunder. In such event, the provisions hereinabove specified in
respect of compensation in lieu of notice shall apply mutatis mutandis, with the date of the change of duties being the date of severance, unless otherwise mutually agreed. 

If
you receive notice that your services will no longer be required or if you suffer what would constitute a demotion resulting in constructive dismissal (in the context of an employer-employee
relationship), as provided above, share options continue to become vested until the first anniversary of the date of severance. In accordance with your Stock Option Agreements, the expiry date for all
vested share options will be the second anniversary of the date of severance or the expiry date of your options, whichever is sooner. 

In
the event of cessation of your employment by reason of death or disability, you (or your designated beneficiary or estate) will be entitled to all rights available to you under the Company's
benefit and compensation plans applicable in the case of death or disability which were in effect at the time of death or disability in lieu of this agreement. Your death or disability after you are
eligible to receive severance payments under this agreement shall not affect the obligation of the Company to make such payments. 

	B.
	Change of Control

If
during the term of your employment there should be a "Change of Control", as defined in Exhibit A attached hereto, and thereafter: 

	(i)
	you
do not serve as Vice President and General Manager Synthetic Biologics Business Unit (or in a position of similar, comparable or more senior authority) for at least
two calendar years or during such period of two years your service with the Company should terminate for any reason in either case other than voluntary resignation, death, disability, just cause or
retirement at or after your normal retirement date under the Company's retirement plans, or

	(ii)
	you
voluntarily resign your position at the Company within one year of a Change of Control as a result of a good faith determination that, as a result of the Change of
Control, you are constructively dismissed (in the context of an employer-employee relationship) from the position you occupied immediately prior to such Change of Control. 

The
Company will pay to you in lieu of any rights, other than those accrued as of the date of termination under the Company's retirement or option plans, an amount equal to (a) one and
one-half (1.5) times amount of your annual salary amount in effect at the time of Change of Control, (b) the annual bonus amount, if any, paid to you in relation to the immediately
preceding fiscal year, and (c) an additional sum equal to 20% of your annual salary then in effect in lieu of any further benefits under this agreement, except to the extent these would 

2

 

already
have accrued or been earned by you under the Company's retirement or option plans (all benefits cease as of the date of severance). 

The
sum of these amounts (a), (b) and (c) shall be paid in equal monthly installments, over eighteen (18) months. 

In
the event of a bona fide threat of a takeover bid for voting control of the Company, the Secretary shall be required to estimate, prior to the occurrence of a Change of Control, the extent to which
you might receive a payment under this Agreement should your employment be terminated as a result thereof. Such estimate by the Secretary and the method of its calculation shall be certified by the
Company's auditors as being consistent with the terms of this agreement and shall, in the absence of
compelling evidence to the contrary, be deemed to be conclusive and binding upon the parties hereto. Subject to the direction and approval of the Board of Directors, the Secretary may set up a reserve
and set aside sufficient funds to permit payment of the aforesaid amount to you. It is further understood and agreed that if your services are terminated as a result of a Change in Control, the expiry
date for share options vested in accordance with your Stock Option Agreements will be the second anniversary of the date of severance or the expiry date of your options, whichever is sooner. 

In
the event of the cessation of your employment after a Change of Control by reason of death or disability, you (or your designated beneficiary or estate) will be entitled to all rights available to
you under the Company's benefit and compensation plans applicable in the case of death or disability which were in effect immediately prior to the Change of Control or, if greater, in effect at the
time of death or disability, in lieu of any compensation under this agreement. Your death or disability after you are eligible to receive severance payments under this agreement shall not affect the
obligation of the Company to make such payments. 

If
you should be entitled to receive payments from the Company on account of termination of your employment under the terms of another employment or severance agreement, or under the terms of
applicable laws and regulations, such other payments shall be in lieu of payments under this agreement and payments under this agreement shall discharge pro tanto  such other amounts due to you.

	2.
	Termination for Cause or Just Cause  

Notwithstanding
the foregoing provisions hereof, should your employment be terminated for "cause" or "just cause", as that term is interpreted according to the laws of the State or Province where you
were based immediately prior to your termination, you shall only be entitled to be compensated, as determined by a court of competent jurisdiction in such State or Province. 

If
you should be entitled to receive payments from the Company on account of termination of your employment under the terms of another employment or severance agreement, or under the terms of
applicable laws and regulations, such other payments shall be in lieu of payments under this agreement and payments under this agreement shall discharge pro tanto such other amounts due to you. 

	3.
	Resignation  

Should
you resign your employment voluntarily, you will not be entitled to receive any payments from the Company on account of the cessation of your employment. 

3

 

        IN WITNESS WHEREOF this Severance Agreement has been executed by the parties hereto. 

	 	 	 	 	BIOMIRA INC.
	

 	
 	

 	
 	

By:	

/s/ Alex McPherson, M.D., Ph.D.
 Alex McPherson, M.D., Ph.D.

President & CEO
	

 	
 	

 	
 	

By:	

/s/ Edward Taylor
 Edward Taylor

Corporate Secretary
	

SIGNED, SEALED AND DELIVERED	
 	

}	
 	

 	

 
	in the presence of	 	}	 	 	 
	 	 	}	 	 	/s/ Rao Koganty
	 	 	}	 	 	
 Rao Koganty
	/s/ Paul Bokenfohr
 Witness Signature	 	}	 	 	 
	

P. Bokenfohr
 Printed Name	
 	

 	
 	

 	

 

4

 
 
 

Exhibit A    
    

        "Change of Control" shall be deemed to have taken place if (1) a third person, including a group working in concert, becomes the beneficial owner of shares
of Biomira Inc. (the "Company" having 25% or more of the total number of votes that may be cast for the election of directors of the Company or (2) there occurs any cash tender or
exchange offer, amalgamation or other business combination, sale of assets or contested election, or any combination of the foregoing transactions, and as a result of or in connection with either
(1) or (2), persons who were directors of the Company before the event shall cease to constitute a majority of the Board of Directors of the Company or any successor to the Company. 

5

QuickLinks

BIOMIRA SEVERANCE AGREEMENT

Exhibit A

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}]]